SDC1 and Miyoshi myopathy: While direct comparison between NNU219 and bortezomib in primary cultures was precluded by the relatively small number of CD138+ cells isolated from these patients, a significant dose-dependent decrease in viability of the cells from all MM patients was observed after NNU219 treatment (Figure 2C; p < 0.001 for all patient samples).